Overview
- On Thursday the Asociación Española Contra el Cáncer marked World Cancer Research Day and publicly reiterated its aim to exceed 70% overall cancer survival by 2030.
- The charity says it has built a national research network funded with about €157–160 million across roughly 800 projects in 160 centres involving more than 3,000 researchers.
- AECC highlighted a 2026 preclinical breakthrough in a HER2+ breast cancer program that produced complete tumor regression in models and has moved into a phase I clinical trial.
- Neuro‑oncology work drew attention in Córdoba, where AECC‑backed efforts include a project that identified new therapeutic markers for oligodendroglioma and a separate program receiving over €10 million to study glioblastoma treatments.
- AECC presented impact figures to justify public support, citing 37 promoted clinical trials, about €2.5 mobilized for every euro invested, 430 jobs generated last year, and rising cancer incidence that underpins the need for sustained funding and trials.